English
French
Press Release
|
19 |
Dec 2019 |
IntelGenx Files Preliminary Short Form Prospectus in Connection With a Proposed Offering of Units... |
|
06 |
Dec 2019 |
IntelGenx Announces Issuance of Shares in Payment of Interest on Outstanding Debentures... |
|
03 |
Dec 2019 |
IntelGenx to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference... |
|
07 |
Nov 2019 |
IntelGenx Reports Third Quarter 2019 Financial Results... |
|
01 |
Nov 2019 |
IntelGenx to Report Third Quarter 2019 Financial Results on November 7, 2019 – Conference Call to Follow... |
|
31 |
Oct 2019 |
IntelGenx Initiates Scale-Up Work for Cannabis-Infused Oral Film Product... |
|
22 |
Oct 2019 |
IntelGenx Announces FDA’s Acceptance of Resubmitted RIZAPORT® New Drug Application... |
|
09 |
Oct 2019 |
IntelGenx Receives Positive DSMB Recommendation for Montelukast VersaFilm® Phase 2a Trial... |
|
26 |
Sep 2019 |
IntelGenx Announces Resubmission of RIZAPORT® New Drug Application... |
|
03 |
Sep 2019 |
IntelGenx to Present at the H.C. Wainwright 21st Annual Global Investment Conference... |
|
08 |
Aug 2019 |
IntelGenx Reports Second Quarter 2019 Financial Results... |
|
01 |
Aug 2019 |
IntelGenx to Report Second Quarter 2019 Financial Results on August 8, 2019 – Conference Call to Follow... |
|
10 |
Jul 2019 |
IntelGenx to Present at 12th Edition of Clinical Trials on Alzheimer’s Disease... |
|
19 |
Jun 2019 |
IntelGenx Announces Addition of Peterborough’s Kawartha Centre as Montelukast VersaFilm® Phase 2a Clinical Trial Site... |
|
10 |
Jun 2019 |
IntelGenx Announces Addition of Ottawa Montelukast VersaFilm® Phase 2a Clinical Trial Site; First Patient in Study Comp... |
|
28 |
May 2019 |
IntelGenx Receives First Shipment of Cannabis Extract from Tilray® for Production of Cannabis-Infused Oral Film... |
|
23 |
May 2019 |
IntelGenx to Join the Quebec Pavilion at BIO 2019 International Convention... |
|
09 |
May 2019 |
IntelGenx Reports First Quarter 2019 Financial Results... |
|
08 |
May 2019 |
IntelGenx Announces the Appointment of André Godin as President and Chief Financial Officer... |
|
08 |
May 2019 |
IntelGenx and Aquestive Therapeutics Enter Worldwide Collaboration Agreement for Tadalafil... |
|
02 |
May 2019 |
IntelGenx to Report First Quarter 2019 Financial Results on May 9, 2019 – Conference Call to Follow... |
|
01 |
May 2019 |
IntelGenx Announces Issuance of Second U.S. Patent for Topical Oral Film Technology... |
|
25 |
Apr 2019 |
IntelGenx to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference... |
|
23 |
Apr 2019 |
IntelGenx to Promote Oral Films CDMO Services at CPhI North America... |
|
16 |
Apr 2019 |
IntelGenx Files Non-Provisional U.S. Patent Application for Oil-Based Active Ingredients... |
|
08 |
Apr 2019 |
IntelGenx to Promote VetaFilm™ Oral Film Technology at Human Biotech & Animal Health Business Partnering Summit... |
|
04 |
Apr 2019 |
IntelGenx Presents at 14th International Conference on Alzheimer’s and Parkinson’s Disease... |
|
02 |
Apr 2019 |
IntelGenx Receives Complete Response Letter from FDA for RIZAPORT® NDA... |
|
27 |
Mar 2019 |
IntelGenx Grants Stock Options... |
|
22 |
Mar 2019 |
IntelGenx Reports Fourth Quarter and Full-Year 2018 Financial Results... |
|
18 |
Mar 2019 |
CORRECTION - IntelGenx to Report Fourth Quarter and Full-Year 2018 Financial Results on March 22, 2019 – Conference Ca... |
|
18 |
Mar 2019 |
IntelGenx to Report Fourth Quarter and Full-Year 2018 Financial Results on March 25, 2019 – Conference Call to Follow... |
|
14 |
Feb 2019 |
IntelGenx Announces Montreal’s Douglas Mental Health University Institute as Ninth Montelukast VersaFilm™ Phase 2a C... |
|
11 |
Feb 2019 |
IntelGenx Granted Japanese Patent for RIZAPORT® VersaFilm™... |
|
07 |
Feb 2019 |
IntelGenx Strengthens Senior Management Team... |
|
30 |
Jan 2019 |
IntelGenx Facility Undergoes U.S. FDA Pre-Approval Inspection Related to RIZAPORT® NDA... |
|
23 |
Jan 2019 |
IntelGenx Provides Update on Phase 2a Montelukast VersaFilm™ Clinical Trial... |
|
14 |
Jan 2019 |
IntelGenx Provides Update on Cannabis-Infused VersaFilm™ Program Following Recently Proposed Amendments to the Cannabi... |